Group D (dexmedetomidine group)

Preclinical

FFayoum University Hospital

Group D (dexmedetomidine group) is one of 3 therapeutic programs targeting Sore Throat. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Sore ThroatRecruiting

Sore ThroatPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Sore Throat

#DrugCompanyPhaseTrials

Benzydamine Hydrochloride

SSeoul National University Hospital

Phase 1

1 2

Group L

SSeoul National University Hospital

Preclinical

1 3

Group D (dexmedetomidine group)

FFayoum University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Sore Throat

NCT07780760

Clinical

Trials by Indication[1]

Sore Throat1 trial

Effect of Preoprative Nebulized Dexmedetomidine Compared to Nebulized Lidocaine in Attenuating Sore Throat Following Tonsillectomy In Childern. A Prospective, Randomized, Double-Blinded Trial.

Recruiting·FFayoum University Hospital·Preclinical·NCT07780760·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Group D (dexmedetomidine group). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Group D (dexmedetomidine group). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fayoum University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: FFayoum University Hospital

Group D (dexmedetomidine group)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Sore Throat1 trial

References

Drug Info

Quick Facts

Related News